Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Inclusion Criteria

• •Patient must have a confirmed diagnosis of:
• •* De novo DLBCL including the clinical subtypes of primary mediastinal, - cell/histiocyte-rich large B-cell lymphoma and intravascular DLBCL OR
• •* De novo transformed DLBCL from follicular lymphoma (FL) OR
• •* Any high grade CD20+ B-cell lymphoma per World Health Organization (WHO) 2016 OR
• •* CD20+ aggressive B-cell lymphoma unclassifiable.
• •Patient must be deemed an appropriate candidate for R-CHOP therapy.
• •Patients must be naive to prior therapy for the study diagnosis.
• •Patient must have advanced stage III/IV early stage disease where provider determines single modality therapy with chemo-immunotherapy is most appropriate (i.e radiation deferred).
• •Patient must have measurable disease (defined as \>= 1.5 cm in diameter) with correlated fludeoxyglucose F-18 (FDG)-avidity on positron emission tomography (PET) scan with Deauville score of 4 or 5 at time of diagnosis.
• •Patient must have Eastern Cooperative Oncology Group (ECOG) performance status =\< 2.
• •Absolute neutrophil count (ANC) \>= 1000/mm\^3, independent of growth factor support or \>= 500/mm\^3 in cases of ongoing bone marrow involvement (in either case, these must be independent of transfusion support) documented =\< 28 days prior to registration.
• •Platelets \>= 100,000/mm\^3, or \>= 50,000 in cases of ongoing bone marrow involvement (In either case, these must be independent of transfusion support) documented =\< 28 days prior to registration.
• •Total bilirubin =\< 1.5 x upper limit of normal (ULN) documented =\< 28 days prior to registration.
• •Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) /alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SPGT\]) =\< 3 x ULN documented =\< 28 days prior to registration.
• •Creatinine clearance \>= 25 mL/min documented =\< 28 days prior to registration.
• •Females of child-bearing potential (FOCBP) and men who are sexually active with FOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment and the designated post-treatment period.
• •* NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
• •* Has not undergone a hysterectomy or bilateral oophorectomy.
• •* Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \> 12 months).
• •Females of childbearing potential (FOCBP) must have a negative urine or serum pregnancy test within 7 days prior to registration on study.
• •Patients must have the ability to understand and willingness to sign a written informed consent prior to registration on study.